Transarterial embolization therapies can be used as palliative treatments or as bridge to transplant and rely on localized, catheter-based delivery of embolic or therapeutic material to tumors within liver via hepatic arteries
TACE involves localized injection of chemotherapeutic drugs mixed with Lipiodol or drug-eluting beads containing doxorubicin (DEB-DOX)
TARE involves localized placement of glass microspheres embedded with Y-90, providing focal therapeutic radiation source within tumor
CEUS TECHNIQUE
CEUS Protocol Advice
IMAGING
General Features
CT/MR Findings
US Findings
CEUS Findings
Technical Pitfalls and Challenges
Clinical Issues
Treatment and Follow-Up
Selected References
Gummadi S et al: Contrast-enhanced ultrasonography in interventional oncology. Abdom Radiol (NY). ePub, 2018
Gummadi S et al: Contrast-enhanced ultrasound identifies early extrahepatic collateral contributing to residual hepatocellular tumor viability after transarterial chemoembolization. Radiol Case Rep. 13(3):713-718, 2018
Nam K et al: Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. Biomed Phys Eng Express. 4(3):035039, 2018
Shaw CM et al: Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. J Ultrasound Med. 34(5):859-67, 2015
Barr RG: Off-label use of ultrasound contrast agents for abdominal imaging in the United States. J Ultrasound Med. 32(1):7-12, 2013
Claudon M et al: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 39(2):187-210, 2013
Takizawa K et al: Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 82(9):1471-80, 2013
Brown DB et al: Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 23(3):287-94, 2012
Xu HX et al: Treatment response evaluation with three-dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol. 76(1):81-8, 2010
Kono Y et al: Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 18(1 Pt 1):57-65, 2007
Related Anatomy
Loading...
Related Differential Diagnoses
Loading...
References
Tables
Tables
KEY FACTS
Terminology
Imaging
TERMINOLOGY
Abbreviations
Transarterial chemoembolization (TACE)
Transarterial radioembolization (TARE)
Definitions
Transarterial embolization therapies can be used as palliative treatments or as bridge to transplant and rely on localized, catheter-based delivery of embolic or therapeutic material to tumors within liver via hepatic arteries
TACE involves localized injection of chemotherapeutic drugs mixed with Lipiodol or drug-eluting beads containing doxorubicin (DEB-DOX)
TARE involves localized placement of glass microspheres embedded with Y-90, providing focal therapeutic radiation source within tumor
CEUS TECHNIQUE
CEUS Protocol Advice
IMAGING
General Features
CT/MR Findings
US Findings
CEUS Findings
Technical Pitfalls and Challenges
Clinical Issues
Treatment and Follow-Up
Selected References
Gummadi S et al: Contrast-enhanced ultrasonography in interventional oncology. Abdom Radiol (NY). ePub, 2018
Gummadi S et al: Contrast-enhanced ultrasound identifies early extrahepatic collateral contributing to residual hepatocellular tumor viability after transarterial chemoembolization. Radiol Case Rep. 13(3):713-718, 2018
Nam K et al: Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. Biomed Phys Eng Express. 4(3):035039, 2018
Shaw CM et al: Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. J Ultrasound Med. 34(5):859-67, 2015
Barr RG: Off-label use of ultrasound contrast agents for abdominal imaging in the United States. J Ultrasound Med. 32(1):7-12, 2013
Claudon M et al: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 39(2):187-210, 2013
Takizawa K et al: Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 82(9):1471-80, 2013
Brown DB et al: Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 23(3):287-94, 2012
Xu HX et al: Treatment response evaluation with three-dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol. 76(1):81-8, 2010
Kono Y et al: Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 18(1 Pt 1):57-65, 2007
STATdx includes over 200,000 searchable images, including x-ray, CT, MR, and ultrasound images. To access all images, please log in or subscribe.